Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 1.00 |
| ▸ | PKM | P14618 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | KAT2B | Q92831 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.68 |
| ▸ | HPGD | P15428 | 3/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL27785592 | 0.92 | KDM4E (0.85) | KDM4EPKMLMNAADORA3ADORA2A | |
| SCHEMBL316035 | 0.86 | KDM4E (0.75) | KDM4EPKMLMNAADORA3ADORA2A | |
| SCHEMBL10242704 | 0.84 | KDM4E (0.73) | KDM4EPKMLMNAADORA3ADORA2A | |
| Hydrochloric Acid SCHEMBL19118816 | 0.84 | KDM4E (0.73) | KDM4EPKMLMNAADORA3ADORA2A | |
| SCHEMBL6263444 | 0.84 | KDM4E (0.72) | KDM4EPKMLMNAADORA3ADORA2A | |
| Hydrochloric Acid SCHEMBL6313771 | 0.83 | KDM4E (0.70) | KDM4EPKMLMNAADORA3ADORA2A | |
| SCHEMBL193027 | 0.83 | KDM4E (0.71) | KDM4EPKMLMNAADORA3ADORA2A | |
| SCHEMBL28972303 | 0.82 | KDM4E (0.69) | KDM4EPKMLMNAADORA3ADORA2A | |
| SCHEMBL6263442 | 0.81 | KDM4E (0.67) | KDM4EPKMLMNAADORA3ADORA2A | |
| SCHEMBL6312721 | 0.80 | KDM4E (0.72) | KDM4EPKMLMNAADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | claimed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | claimed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
| WO-2018106818-A1 | METHODS OF PROMOTING BETA CELL PROLIFERATION | KURA ONCOLOGY, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| EP-2473054-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF LEUKEMIA | UNIV MICHIGAN REGENTS (US) | 2017-06-14 | — | — | EP | disclosed |
| US-8993552-B2 | Compositions and methods for treatment of leukemia | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993552-B2 | Compositions and methods for treatment of leukemia | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-03-31 | — | — | US | disclosed |
| US-20110065690-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF LEUKEMIA | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110065690-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF LEUKEMIA | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110065690-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF LEUKEMIA | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-03-17 | — | — | US | disclosed |
| WO-2011029054-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF LEUKEMIA | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-03-10 | — | — | WO | disclosed |
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2L, ATXN2, ATXN10 | KDM4E 2537/4885PKM 4107/4885LMNA 1046/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | KDM4E 2603/4885PKM 4523/4885LMNA 2020/4885 |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | KDM4E 2603/4885PKM 4523/4885LMNA 2020/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | KDM4E 2182/4885PKM 3287/4885LMNA 1719/4885 |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | KDM4E 1190/4885PKM 2145/4885LMNA 3391/4885 |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | KDM4E 3446/4885PKM 359/4885LMNA 2123/4885 |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | KDM4E 3066/4885PKM 2791/4885LMNA 188/4885 |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, UBQLN2, UBTF | KDM4E 1993/4885PKM 4671/4885LMNA 2841/4885 |
| US-20110065690-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF LEUKEMIA | MLLT1, MCL1, MLLT3 | KDM4E 444/4885PKM 3249/4885LMNA 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.